Pneumococcal meningitis in a patient with severe COVID-19 on dexamethasone and tocilizumab: a case report

Although various therapeutic agents have been tried for coronavirus disease-2019 (COVID-19) and evidence has accumulated, the risk of secondary infection is increased by underlying disease and immunosuppressive drugs. We report a case of pneumococcal meningitis in a patient with severe COVID-19 who was receiving dexamethasone and tocilizumab. The patient's symptoms improved with appropriate diagnosis and antimicrobial therapy, and he fortunately returned to society without any neurological sequelae of meningitis.